Laboratory Monitoring of OxyContin (Oxycodone): Clinical Pitfalls

Headache

Volumn 44, Issue 1, 2004, Pages 44-47

  Von Seggern, Randal L ^a   Fitzgerald, Charles P ^a   Adelman, Leon C ^a   Adelman, James U ^a  

^a Headache Wellness Center   (United States)

Author keywords

Laboratory; Opioid

Indexed keywords

DEXTROPROPOXYPHENE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; OXYCODONE; PERCOCET;

ADULT; ANALGESIA; ANALGESIC AGENT ABUSE; ANALYTICAL ERROR; ARTICLE; CASE REPORT; DRUG MONITORING; GAS CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MIGRAINE; PATIENT COMPLIANCE; PRIORITY JOURNAL; URINALYSIS;

ADULT; ANALGESICS, OPIOID; CHROMATOGRAPHY; DRUG MONITORING; FALSE NEGATIVE REACTIONS; HEADACHE DISORDERS; HUMANS; IMMUNOASSAY; MALE; OXYCODONE; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION;

EID: 1642527478     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04008.x     Document Type: Article

References (13)

1. Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage. 2000;20:293-307.
2. Hammett-Stabler CA, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clin Chem Acta. 2002;315:125-135.
3. White S, Wong SH. Standards of laboratory practice: analgesic drug monitoring. Clin Chem Acta. 1998;44:1110-1123.
4. Eskridge KD. Clinical issues associated with urine testing of substances of abuse. Pharmacotherapy. 1997;17:497-509.
5. Nowatzke W, Zenga J, Saundersb A, Bohrerc A, Koenigb J, Turka J. Distinction among eight opiate drugs in urine by gas chromatography-mass spectrometry. J Pharm Biomed Anal. 1999;20:815-828.
6. Colbert DL. Drug abuse screening with immunoassays: unexpected cross-reactivities and other pitfalls. Br J Biomed Sci. 1994;51:136-146.
7. Baselt RC. Disposition of toxic drugs and chemicals in man. Chem Toxicol Inst. 2000;5:644-645.
8. Smith ML, Hughes RD, Levine B, Dickerson S, Darwin WD, Cone EJ. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and GC-MS. J Anal Toxicol. 1995;1:18-26.
9. Valdes R Jr, Jortani SA. Unexpected suppression of immunoassay results by cross-reactivity: now a demonstrated cause for concern. Clin Chem Acta. 2002;48:405-406.
10. Fraser AD, Worth D. Experience with a urine opiate screening and confirmation cutoff of 2000 ng/mL. J Anal Toxicol. 1999;23:549-551.
11. Hattab EM, Goldberger BA, Johannsen LM, et al. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci. 2000;30:85-91.
12. Montagne M, Pugh CB, Fink JL 3rd. Testing for drug use, part 1: analytical methods. Am J Hosp Pharm. 1988;45:1297-1305.
13. Augsburger M, Rivier L, Mangin P. Comparison of different immunoassays and GC-MS screening of benzodiazepines in urine. J Pharm Biomed Anal. 1998;18:681-687.